Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B Study to Examine the Pharmacokinetic and Pharmacodynamic Effects of INV-202 in Subjects With Metabolic Syndrome as Defined by Hypertriglyceridemia, Abdominal Obesity, and Impaired Glucose Tolerance Over 28 Days

Next Previous
Trial Profile

A Phase 1B Study to Examine the Pharmacokinetic and Pharmacodynamic Effects of INV-202 in Subjects With Metabolic Syndrome as Defined by Hypertriglyceridemia, Abdominal Obesity, and Impaired Glucose Tolerance Over 28 Days

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Monlunabant (Primary)
  • Indications Metabolic syndrome
  • Focus Adverse reactions
  • Sponsors Inversago Pharma

Most Recent Events

  • 26 Jun 2023 Results reporting safety and efficacy post-hoc data presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
  • 24 Jun 2023 Results published in the Inversago Pharma Media Release
  • 08 Jun 2023 According to Inversago Pharma media release, data from this study will be presented at the 83rd American Diabetes Association Scientific Sessions

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top